Single-use technology is well-established, and has made its way into commercial licensed facilities, but there is more innovation in this field which will further enhance its versatility into new markets and technologies. The closed-system ballroom manufacturing approach will enable biomanufacturers to take full advantage of the flexibility offered by single-use systems, while driving out risk and is particularly suitable for applications that require multiple or rapid change-overs, and therapies with small scale production.
The concept of optionality is key to staying flexible in biomanufacturing by keeping your options open and having multiple pathways to take while navigating through this highly uncertain environment. Using a combination of financial options analysis and decision analytics to quantify your options helps to embrace the uncertainty equation.
Securing a partner to serve as an extension of Janssen’s Biotherapeutics Development API-Large Molecule team was essential to reducing both risk and the time needed for delivery of critical clinical supplies.
By applying remote monitoring solutions, advanced modeling, and optimization of manufacturing processes, Industry 4.0 offers improved process reliability and product quality through unlimited possibilities of connecting machines and data.
Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
This whitepaper discusses cleaning of affinity resins intended for use in the purification of monoclonal antibodies and antibody fragments.
Joe Principe, Vice President of Strategic Partnerships, Patheon, discusses the new set of “must-haves” that are emerging from the increased need for flexibility in outsourced manufacturing partnerships.
Single-use technologies are being seen as the solution to flexibly and cost-effectively address many of the challenges around creating biologics manufacturing capacity.
Pharmaceutical manufacturer and developer, Penn Pharma, has confirmed that its new contained manufacturing facility for producing highly potent products is on track for opening Q1 2013 at an exclusive event held at the British Embassy, Madrid during ICSE.
Nitto Avecia Pharma Services has in-depth experience with a wide range of drug delivery device technologies to offer your programs comprehensive technical support.
How your manufacturing, packaging, serialization, and clinical distribution can benefit with a contract partner.
Piramal Pharma Solutions is the contract development and manufacturing (CDMO) arm of Piramal Enterprises Ltd., having a vast network of development and manufacturing facilities located in North America, Europe and Asia.